Fosun Pharma's (600196.SH) Subsidiary Receives Clinical Trial Approval for HLX37 Injection

Stock News

2025/12/01

Fosun Pharma (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled entities (collectively referred to as "Henlius") recently received approval from the National Medical Products Administration for the clinical trial of HLX37 injection (a recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody injection) in treating patients with advanced/metastatic solid tumors. Henlius plans to initiate a Phase I clinical trial for HLX37 in China once conditions are met. HLX37 is a self-developed recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody by the group, intended for the treatment of advanced/metastatic solid tumors. Preclinical studies to date have demonstrated HLX37's ability to inhibit tumor growth with favorable safety profiles.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1121426684"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121426684\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121426684?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 17:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121426684","market":"sg","top_or_hot":-1,"title":"Fosun Pharma's (600196.SH) Subsidiary Receives Clinical Trial Approval for HLX37 Injection","media":"Stock News","content":"<p>Fosun Pharma (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled entities (collectively referred to as \"Henlius\") recently received approval from the National Medical Products Administration for the clinical trial of HLX37 injection (a recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody injection) in treating patients with advanced/metastatic solid tumors. Henlius plans to initiate a Phase I clinical trial for HLX37 in China once conditions are met. HLX37 is a self-developed recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody by the group, intended for the treatment of advanced/metastatic solid tumors. Preclinical studies to date have demonstrated HLX37's ability to inhibit tumor growth with favorable safety profiles.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma's (600196.SH) Subsidiary Receives Clinical Trial Approval for HLX37 Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma's (600196.SH) Subsidiary Receives Clinical Trial Approval for HLX37 Injection\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-12-01 17:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Fosun Pharma (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled entities (collectively referred to as \"Henlius\") recently received approval from the National Medical Products Administration for the clinical trial of HLX37 injection (a recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody injection) in treating patients with advanced/metastatic solid tumors. Henlius plans to initiate a Phase I clinical trial for HLX37 in China once conditions are met. HLX37 is a self-developed recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody by the group, intended for the treatment of advanced/metastatic solid tumors. Preclinical studies to date have demonstrated HLX37's ability to inhibit tumor growth with favorable safety profiles.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600196","symbol_name":"復星醫藥","start_time":0,"source_url":"","article_id":"1121426684","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121426684","pubTimestamp":1764580217,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Fosun Pharma (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled entities (collectively referred to as \"Henlius\") recently received approval from the National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK1593":"医美概念股","BK0012":"证金概念","BK0175":"白马股","BK0196":"行业龙头","BK0187":"一线龙头","BK1515":"抗疫概念","BK0060":"抗癌","BK1191":"制药","BK0188":"融资融券","BK0028":"国家队","BK0239":"医药制造","02196":"复星医药","BK0183":"MSCI概念","BK0096":"民营医院"},"translate_title":"复星医药（600196.SH）子公司HLX37注射液获临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"Fosun Pharma (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled entities (collectively referred to as \"Henlius\") recently received approval from the National Medical Products Administration for the clinical trial of HLX37 injection (a recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody injection) in treating patients with advanced/metastatic solid tumors. Henlius plans to initiate a Phase I clinical trial for HLX37 in China once conditions are met. HLX37 is a self-developed recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody by the group, intended for the treatment of advanced/metastatic solid tumors. Preclinical studies to date have demonstrated HLX37's ability to inhibit tumor growth with favorable safety profiles.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}